Our firm represented Minovia Therapeutics Ltd. in a de-SPAC transaction with Launch One Acquisition Corp, a NASDAQ-listed SPAC. Upon completion of the transaction, Minovia will become a publicly traded company listed on NASDAQ. The agreement attributes Minovia with a pre-money valuation of USD 180 million. Minovia, which develops groundbreaking treatments for mitochondrial diseases, is expected to use the proceeds from the transaction to further advance and expand its innovative technology platform.
June 30, 2025
